{
    "clinical_study": {
        "@rank": "33504", 
        "acronym": "JAK2", 
        "arm_group": {
            "arm_group_label": "Ruxolitinib", 
            "arm_group_type": "Experimental", 
            "description": "20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is that ruxolitinib may be a possible treatment option for\n      relapsed or refractory patients with Hodgkin and primary mediastinal large B-cell lymphoma."
        }, 
        "brief_title": "Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma", 
        "condition": [
            "Relapsed or Refractory Hodgkin Lymphoma", 
            "Primary Mediastinal Large B-cell Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Lymphoma", 
                "Lymphoma, B-Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically proven Hodgkin lymphoma or primary mediastinal large B-cell lymphoma\n\n          -  Patient should belong to any one of following clinical situations A.Patient who are\n             not able to get autologous stem cell transplantation after relapsing the salvage\n             chemotherapy B. Relapsed after autologous stem cell transplantation C. Refractory to\n             salvage chemotherapy or autologous stem cell transplantation\n\n          -  Adequate organ function as defined by the following criteria:\n\n        A. Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase (SGOT)) and\n        serum alanine transaminase (ALT; serum glutamic pyruvic transaminase (SGPT)) \u22642.5 x local\n        laboratory upper limit of normal (ULN), or AST and ALT less than or equal to 5 x ULN if\n        liver function abnormalities are due to underlying malignancy B. Total serum bilirubin\n        \u22641.5 x ULN C. Absolute neutrophil count (ANC) \u2265 1500/\u00b5L D. Platelets \u2265 100,000/\u00b5L E.\n        Hemoglobin \u2265 9.0 g/dL (may be transfused or erythropoietin treated) F. Serum calcium \u2264\n        12.0 mg/dL G. Serum creatinine \u2264 1.5 x ULN\n\n          -  At least one measurable lesion\n\n          -  ECOG PS 0-2\n\n          -  Informed consent\n\n          -  Age from 19 to 80\n\n        Exclusion Criteria:\n\n          -  Previously received allogeneic stem cell transplantation\n\n          -  History of or known carcinomatous meningitis, or evidence of symptomatic\n             leptomeningeal disease or secondary CNS involvement on CT or MRI scan.\n\n          -  Currently uncontrolled active infection\n\n          -  Previous history of recurrent herpes zoster or recurrent tuberculosis\n\n          -  Ongoing cardiac dysrhythmias of NCI CTCAE grade \u22652.\n\n          -  Pregnant or lactating females or patients who ar not willing to use an adequate\n             method of birth control for the duration of the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01965119", 
            "org_study_id": "SMC 2013-06-039"
        }, 
        "intervention": {
            "arm_group_label": "Ruxolitinib", 
            "description": "20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.", 
            "intervention_name": "Ruxolitinib", 
            "intervention_type": "Drug", 
            "other_name": "jakavi"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 17, 2013", 
        "location": [
            {
                "contact": {
                    "email": "hseom@ncc.re.kr", 
                    "last_name": "Hyeon Seok Eom", 
                    "phone": "82-031-920-2402"
                }, 
                "facility": {
                    "address": {
                        "city": "Goyang-si", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi-do", 
                        "zip": "410-769"
                    }, 
                    "name": "National Cancer Center of Korea"
                }, 
                "investigator": {
                    "last_name": "Hyeon Seok Eom", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "drydh1685@hotmail.com", 
                    "last_name": "Deok-Hwan Yang"
                }, 
                "facility": {
                    "address": {
                        "city": "Hwasun", 
                        "country": "Korea, Republic of", 
                        "state": "Jeollanam-do", 
                        "zip": "519-763"
                    }, 
                    "name": "Chonnam University Hwasoon Hospital"
                }, 
                "investigator": {
                    "last_name": "Deok-Hwan Yang", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "seonghyunmd@naver.com", 
                    "last_name": "Seong Hyun Jeong"
                }, 
                "facility": {
                    "address": {
                        "city": "Suwon", 
                        "country": "Korea, Republic of", 
                        "state": "Kyunggi-do", 
                        "zip": "443-721"
                    }, 
                    "name": "Ajou University Hospital"
                }, 
                "investigator": {
                    "last_name": "Seong Hyun Jeong", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "drbbpark@gmail.com", 
                    "last_name": "Byeong-Bae Park"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "133-792"
                    }, 
                    "name": "Hanyang University Hospital"
                }, 
                "investigator": {
                    "last_name": "Byeong-Bae Park", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "dhyoon@amc.seoul.kr", 
                    "last_name": "Dok Hyun Yoon, PH", 
                    "phone": "82-10-3235-3090"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "138-736"
                    }, 
                    "name": "Asan Medical Center"
                }, 
                "investigator": {
                    "last_name": "Duk Hyun Yoon, PhD.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "paark76@hanmail.net", 
                    "last_name": "Yong Park"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "136-705"
                    }, 
                    "name": "Korea University Anam Hospital"
                }, 
                "investigator": {
                    "last_name": "Yong Park", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "hemakim@yuhs.ac", 
                    "last_name": "Jin Seok Kim", 
                    "phone": "82-2-2228-1972"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "120-752"
                    }, 
                    "name": "Yonsei Medical Center"
                }, 
                "investigator": {
                    "last_name": "Jin Seok Kim", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "hyejin@kcch.re.kr", 
                    "last_name": "Hye Jin Kang", 
                    "phone": "82-10-2980-9262"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "139-706"
                    }, 
                    "name": "Korean Cancer Center Hospital"
                }, 
                "investigator": {
                    "last_name": "Hye Jin Kang", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "yeungchul@ewha.ac.kr", 
                    "last_name": "Young Chul Moon"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "158-710"
                    }, 
                    "name": "Ehwa Womens University Hospital"
                }, 
                "investigator": {
                    "last_name": "Young Chul Moon", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell Lymphoma", 
        "overall_contact": {
            "email": "wonseog.kim@samsung.com", 
            "last_name": "Won Seog Kim, PhD", 
            "phone": "82-2-3410-6548"
        }, 
        "overall_contact_backup": {
            "email": "seokjin88.kim@samsung.com", 
            "last_name": "Seok Jin Kim, PhD", 
            "phone": "82-2-3410-1766"
        }, 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "Won Seog Kim, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "South Korea: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To assess the efficacy of disease control  including complete response (CR), partial response (PR) and stable disease (SD)", 
            "safety_issue": "Yes", 
            "time_frame": "From date of enrollment until the date first documented disease progression or unacceptable toxicity, whichever came first, assessed up to 48months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01965119"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Samsung Medical Center", 
            "investigator_full_name": "Won Seog Kim", 
            "investigator_title": "M.D., PhD.", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "CTCAE v4 (Common Terminology Criteria for Adverse Events v4.0) In the present study, toxicities will be recorded according to the National Cancer Institute Common Terminology Criteria for Adverse Event (CTCAE), version 4.0. The full CTCAE documentation is available on the NCI web site, at the following address: http://ctep.cancer.gov/forms/CTCAEv4.pdf The occurrence of severe adverse event (SAE) should be also reported to the Novartis Safety Office within 24 hours.", 
                "measure": "Toxicity profile", 
                "safety_issue": "Yes", 
                "time_frame": "from the date of informed consent signature to 30days after last drug administration"
            }, 
            {
                "measure": "Overal Survival", 
                "safety_issue": "Yes", 
                "time_frame": "from the date of first drug administration until the date of death, assessed up to 48months"
            }
        ], 
        "source": "Samsung Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Samsung Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}